MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:40Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Progestogens]]
			[[Category:Hormonal contraceptives]]
			[[Category:Sex hormones]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #257

2026-05-23T04:08:51Z

parser-claude batch MedTemplate pre-fill, Top 300 #257

New page

{{MedTemplate
| generic = Medroxyprogesterone acetate (MPA)
| brand = Provera (oral), Depo-Provera (IM contraceptive), Depo-SubQ Provera 104 (SC)
| structure =
| classes = [[:Category:Progestogens|Progestin (synthetic progestogen)]], [[:Category:Hormonal_contraceptives|Hormonal contraceptive (Depo)]], [[:Category:Sex_hormones|Sex hormone]]
| uses = <vote slug="contraception-depot-use">Long-acting reversible contraception (Depo-Provera)</vote>, <vote slug="endometriosis-use">Endometriosis</vote>, <vote slug="amenorrhea-use">Secondary amenorrhea</vote>, <vote slug="hrt-endometrial-protection-use">Endometrial protection in estrogen-containing HRT</vote>, <vote slug="endometrial-cancer-use">Selected endometrial cancer (palliative/adjunct)</vote>
| starting_dose = Contraception: Depo-Provera 150 mg IM every 13 weeks; Depo-SubQ 104 mg SC every 12-13 weeks; oral cycling: 5-10 mg PO daily ×5-10 days for amenorrhea
| preparations = 2.5, 5, 10 mg oral tablets; Depo-Provera 150 mg/mL IM; Depo-SubQ Provera 104 mg/0.65 mL
| fda_max = Indication-specific
| pill_id =
| routes = Oral, IM, SC
| onset = Contraceptive within 24 hours if given in first 5 days of cycle; otherwise backup for 7 days
| duration = Depot IM 13 weeks (designed); often persists longer
| halflife = ~50 days (Depo-Provera; long depot release)<ref name="depo-provera-label">FDA Prescribing Information, Depo-Provera (medroxyprogesterone acetate), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020246s036lbl.pdf</ref>
| bioavailability = Oral ~90%; depot IM essentially 100% over the dosing interval<ref name="depo-provera-label" />
| pregnancy = Contraindicated in known pregnancy.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for bone mineral density loss with prolonged use (≥2 years; partially reversible after discontinuation)<ref name="depo-provera-label" />
| mechanism = <vote slug="mpa-mech-claim">Medroxyprogesterone is a synthetic 17α-hydroxyprogesterone derivative that binds progesterone receptors with high affinity (also weak androgen receptor binding); it suppresses gonadotropin release (LH surge) to inhibit ovulation, thickens cervical mucus, and atrophies endometrium — combined contraceptive mechanism.</vote> Unlike bioidentical progesterone, MPA has been associated in the WHI substudies with increased breast cancer and cardiovascular risk relative to estrogen-alone HRT, which has shifted some clinical preference toward micronized progesterone for menopausal endometrial protection. Depo bone loss reverses partially over 1-2 years after discontinuation<ref name="depo-provera-label" />.
}}

== References ==
<references />

Medroxyprogesterone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #257